Another milestone as Chimeric Therapeutics’ (ASX:CHM) Phase 1 CLTX CAR T trial moves ahead


  • Chimeric Therapeutics has disclosed that the first patient in the second dose cohort of Phase 1 CLTX CAR T cell trial has received dosing.
  • In April 2021, the oncology firm announced the completion of the follow-up for the first patient cohort.
  • The second dose cohort will be administered at a targeted dose of 88 × 106 CLTX CAR T cells without a mandated stagger.

In another significant development, Chimeric Therapeutics Limited (ASX:CHM) has updated the market that its Phase 1 clinical trial of chlorotoxin CAR T (CLTX CAR T) cell therapy has initiated the second dose cohort. The Company disclosed that the first patient in the study had received dosing.

The Phase 1 trial is being carried out to evaluate the safety and tolerability of CLTX CAR T cells at City of Hope, a world-renowned cancer treatment and research centre. In April 2021, Chimeric Therapeutics completed the follow-up interval for the first patient cohort in CLTX CAR T trial. Following the safety milestone achieved for the CLTX CAR T cell therapy, the study has moved to a higher dose level.

 ALSO READ: Chimeric Therapeutics’ (ASX:CHM) clinical trial hits a key milestone, progresses to next level

Intratumoral and Intraventricular dosing of CLTX CAR T cells

The initiation of the second dose cohort introduces the dual administration of CLTX CAR T cells. The cells will now be administered via intracranial intratumoral (ICT) and intracranial intraventricular (ICV) routes. Additionally, the second dose cohort will facilitate dosing without a mandated stagger and will be given a total target dose of 88 × 106 CLTX CAR T cells.

Staggered dosing is a method of dose administration that necessitates a follow-up period between the doses administered to one patient and the next patient. This allows sequential treatment with an adequate interval to observe the adverse reactions between the doses.

The Phase 1 clinical trial is anticipated to enrol 18-36 patients with glioblastoma (MMP2+ progressive or recurrent), an aggressive form of brain tumour, across a 24-month period.

DO READ: Chimeric Therapeutics bringing innovation to the fore with its CLTX CAR T Therapy

Source: CHM Presentation

Jennifer Chow, Chief Operating Officer of Chimeric Therapeutics, commented-

ALSO READ: Meet the leadership team behind Chimeric Therapeutics’ innovative CLTX-CAR T therapy

CLTX CAR T Cell Therapy in a nutshell

  • CLTX CAR T cell therapy is a potentially best-in-class therapy with the ability to address the unmet medical need of patients with glioblastoma (GBM).
  • Research for developing the intellectual property (IP) covering CLTX CAR T cell therapy was held at City of Hope.
  • CLTX has been proven to bind more specifically to GBM cells in preclinical models than any other targets such as HER2, EGFR, or IL13Rα2.
  • CLTX CAR T cells also demonstrated potent antitumour activity with optimal safety and efficacy profile in preclinical studies.

DO READ: Using scorpion venom to treat tumours: A look at Chimeric Therapeutics' CLTX technology

On 25 May 2021, CHM shares were trading at AU$0.285 (at AEST 10:46 AM).   





Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK